T-cell-engaging bispecific antibodies (BsAbs) simultaneously bind to antigens on tumour
cells and CD3 subunits on T cells. This simultaneous binding results in the recruitment of T …

Abstract Treatment paradigms for B-cell non-Hodgkin lymphomas (B-NHL) have shifted
dramatically in the last 2 decades following the introduction of highly active …

Background Odronextamab is a hinge-stabilised, fully human IgG4-based CD20× CD3
bispecific antibody that binds CD3 on T cells and CD20 on B cells. We aimed to evaluate the …

Follicular lymphoma, the most common indolent lymphoma, though highly responsive to
therapy is coupled with multiple relapses for the majority of patients. Advances in biologic …

Diffuse large B-cell lymphoma (DLBCL) is an aggressive but potentially curable disease and
is most common in older people. Rituximab-CHOP (cyclophosphamide, doxorubicin …

Follicular lymphoma (FL) is the most common indolent lymphoma and is characterized by a
relapsing and remitting course. In addition to significant biologic heterogeneity, the clinical …

Cancer is the second leading cause of death worldwide after cardiovascular diseases.
Harnessing the power of immune cells is a promising strategy to improve the antitumor effect …

Mantle cell lymphoma (MCL) is a rare type of B-cell Non-Hodgkin lymphoma (NHL) affecting
predominantly male patients. While complete remissions following first-line treatment are …

Follicular lymphoma (FL) is the most common indolent non‐Hodgkin lymphoma subtype,
accounting for 15–20% of all lymphoma diagnoses. Although typically slow‐growing and …

Follicular lymphoma (FL), a generally indolent disease that derives from germinal center
(GC) B cells, represents around 20–25% of all new lymphomas diagnosed in Western …